Andrographis для Upper Respiratory Tract Infections
B Доказательства По меньшей мере одно рандомизированное исследование подтверждает это, с в целом согласованными результатами.Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'immunecited.com';
const params = 'ingredient\u003Dandrographis\u0026condition\u003Dupper\u002Drespiratory\u002Dinfections';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
Итог
Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.
Key Study Findings
Randomized Controlled Trial
n=331
1.0 weeks
Double-blind
Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common …
Dose: 200 mg/day
или: placebo
Outcome: URTI symptom severity
Эффект: None
p = 0.034
Популяция: Participants with uncomplicated URTI
Review
A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead …
Dose: None
или: None
Outcome: URTI symptom severity
Эффект: None
None
Популяция: COVID-19/URTI patients
Review
Plant-Based Support of Respiratory Health during Viral Outbreaks.
Dose: None
или: None
Outcome: None
Эффект: None
None
Популяция: None
Other
n=179
Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.
Dose: 60 mg
или: placebo
Outcome: None
Эффект: None
p = 0.0053
Популяция: None
Meta-Analysis
n=1000
Safety of Andrographis paniculata: A systematic review and meta-analysis.
Dose: 95%
или: control
Outcome: None
Эффект: None
None
Популяция: upper respiratory tract infection
Other
In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa.
Dose: 6 μg/mL
или: Control group
Outcome: None
Эффект: None
None
Популяция: None
Key Statistics
7
Исследования
800
Участники
↑
Positive
B
Оценка
Referenced Papers
Complementary therapies in …
2023
6 цитирований
Molecules (Basel, Switzerland)
2022
80 цитирований
Journal of agricultural …
2022
9 цитирований
Pharmacoepidemiology and drug …
2021
32 цитирований
Journal of traditional …
2021
9 цитирований
Brazilian journal of …
2020
45 цитирований
Cell death & …
2019
160 цитирований
Biomedicine & pharmacotherapy …
2019
103 цитирований
Phytomedicine : international …
2010
107 цитирований
Alternative medicine review …
2007
163 цитирований
American journal of …
2006
51 цитирований
Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy.
Systematic Review
Planta medica
2004
262 цитирований
Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials.
Systematic Review
Journal of clinical …
2004
157 цитирований
Primary care
2002
56 цитирований
Journal of the …
1990
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Часто используемые дозировки
- acute:
- 400 mg 3x/day for up to 7 days
- general:
- 200 mg standardized extract (30% andrographolides) 2x/day
Верхний предел: No established UL; short-term use (<14 days)
Дозировки, изученные в исследованиях
| Дозировка | Длительность | Эффект | N |
|---|---|---|---|
| 200 mg/day | 1.0 weeks | Positive | 331 |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| 60 mg | -- | Positive | 179 |
| 95% | -- | Neutral | 1000 |
| 6 μg/mL | -- | Positive | -- |
| None | -- | Mixed | -- |
| 18 G | 4.0 weeks | Mixed | -- |
Лучшее время приёма: At first sign of symptoms; with meals
Safety & Side Effects
Зарегистрированные побочные эффекты
- ⚠ Gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Headache
- ⚠ Fatigue
- ⚠ Allergic reactions (rare)
- ⚠ Potential anti-fertility effects (high doses in animal studies)
Известные взаимодействия
- ● Anticoagulant and antiplatelet drugs (may increase bleeding risk)
- ● Antihypertensive medications (additive blood pressure lowering)
- ● Immunosuppressant medications (may counteract immunosuppression)
Допустимый верхний уровень потребления: No established UL; short-term use (<14 days)
Всегда консультируйтесь с врачом перед началом приёма любых добавок.Всегда консультируйтесь с лечащим врачом перед началом приёма любой добавки.
Frequently Asked Questions
Does Andrographis help with Upper Respiratory Tract Infections?
Based on 7 studies with 800 participants, there is moderate evidence from clinical studies that Andrographis may support Upper Respiratory Tract Infections management. Our evidence grade is B (Good Evidence).
How much Andrographis should I take for Upper Respiratory Tract Infections?
Studies have used various dosages. A commonly studied range is 400 mg 3x/day for up to 7 days. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Andrographis?
Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Headache, Fatigue, Allergic reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Andrographis and Upper Respiratory Tract Infections?
We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.
Related Evidence
Другие ингредиенты для Upper Respiratory Tract Infections
References
- [1] Jeffrey Pradeep Raj et al.. Complement Ther Med. 2023. Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, … doi:10.1016/j.ctim.2023.102934 PubMed
- [2] Aekkhaluck Intharuksa et al.. Molecules. 2022. A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery. doi:10.3390/molecules27144479 PubMed
- [3] Thirumurugan Rathinasabapathy et al.. J Agric Food Chem. 2022. Plant-Based Support of Respiratory Health during Viral Outbreaks. doi:10.1021/acs.jafc.1c06227 PubMed
- [4] Wiwan Worakunphanich et al.. Pharmacoepidemiol Drug Saf. 2021. Safety of Andrographis paniculata: A systematic review and meta-analysis. doi:10.1002/pds.5190 PubMed
- [5] Mikayel Narimanyan et al.. J Tradit Complement Med. 2021. Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study. doi:10.1016/j.jtcme.2021.06.001 PubMed
- [6] Moumita Majumdar et al.. Braz J Microbiol. 2020. In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa. doi:10.1007/s42770-019-00169-0 PubMed
- [7] Jian Gao et al.. Cell Death Dis. 2019. Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. doi:10.1038/s41419-019-2195-8 PubMed
- [8] Jiashu Lu et al.. Biomed Pharmacother. 2019. A review for the neuroprotective effects of andrographolide in the central nervous system. doi:10.1016/j.biopha.2019.109078 PubMed
- [9] R C Saxena et al.. Phytomedicine. 2010. A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory … doi:10.1016/j.phymed.2009.12.001 PubMed
- [10] Mario Roxas et al.. Altern Med Rev. 2007. Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. PubMed
- [11] Roxane R Carr et al.. Am J Health Syst Pharm. 2006. Complementary and alternative medicine for upper-respiratory-tract infection in children. doi:10.2146/ajhp040613 PubMed
- [12] Joanna Thompson Coon et al.. Planta Med. 2004. Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. doi:10.1055/s-2004-818938 PubMed
- [13] N Poolsup et al.. J Clin Pharm Ther. 2004. Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. doi:10.1046/j.1365-2710.2003.00534.x PubMed
- [14] Raja Jaber. Prim Care. 2002. Respiratory and allergic diseases: from upper respiratory tract infections to asthma. doi:10.1016/s0095-4543(01)00008-2 PubMed
- [15] A Leelarasamee et al.. J Med Assoc Thai. 1990. Undetectable anti-bacterial activity of Andrographis paniculata (Burma) wall. ex ness. PubMed
Отказ от ответственности FDA: Данные утверждения не были оценены Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA). Продукты и информация на этом сайте не предназначены для диагностики, лечения, излечения или профилактики каких-либо заболеваний. Представленные оценки доказательности основаны на нашем анализе опубликованных рецензируемых исследований и не являются медицинской консультацией. Всегда консультируйтесь с лечащим врачом перед началом приёма любых добавок.